2016 American Transplant Congress
Anti-Angiotensin II Type 1 Receptor Antibody Reduction with Proteasome Inhibitor-Based Desensitization.
University of Cincinnati, Cincinnati.
Background. Desensitization results have largely focused on effects on anti-HLA antibody (HLA-Ab) and anti-ABO antibody levels. Anti-angiotensin II type 1 receptor antibody (AT1R-Ab) has recently…2016 American Transplant Congress
Better Long-Term Renal Function with Lower Incidence of Acute Rejection and Lower CMV Infection in Renal Transplant Patients Treated with a Combination of Tacrolimus and Everolimus.
Surgery - Renal Transplant Unit, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction. Recent clinical trials have shown that the combination of CNIs with Everolimus (EVE) allows CNIs minimization, which may positively impact on chronic nephrotoxicity. Aim…2016 American Transplant Congress
Monitoring of De Novo DSA Post Alemtuzumab Induction in Renal Transplant Recipients: One Year Follow Up.
Nephrology & Hypertension, Stony Brook Medicine, Stony Brook, NY.
IntroductionThe presence of de novo DSA (dnDSA) is associated with antibody mediated rejection and less optimal graft outcomes. The overall incidence of dnDSA post renal…2016 American Transplant Congress
Twenty Years of Evolving Trends in Racial Disparities for Adult Kidney Transplant Recipients.
Med Univ of South Carolina, Charleston, SC.
Objective: To determine if baseline risks and post-transplant outcome disparities in African American (AA) kidney transplant recipients have evolved over time.Methods: Analysis of 20-years of…2016 American Transplant Congress
Understanding the Initial Rise in Kidney Discard Rates Observed Post-KAS.
1UNOS, Richmond, VA; 2Emory Univ, Atlanta, GA; 3Univ Hosp Case Med Ctr, Cleveland, OH.
Background: Kidney discard rates increased by 10% -- from 18.3% to 20.2% (p=0.001) -- during the first 7 months of KAS but returned to pre-KAS…2016 American Transplant Congress
99% and 100% CPRA Patients Since KAS: A Substantial Increase in Transplants with Strong Evidence of a Bolus Effect.
1UNOS, Richmond, VA; 2Univ Hosp Case Med Ctr, Cleveland, OH; 3Emory Univ Hosp, Atlanta, GA.
Background: The Kidney Allocation System (KAS), implemented on 12/4/14, increased allocation priority for candidates with CPRA of 99-100%. Analyses performed on behalf of the OPTN…2016 American Transplant Congress
A Pathway to Belatacept Monotherapy: Alemtuzumab, Belatacept and Rapamycin for Kidney Transplantation.
1Emory Transplant Center, Atlanta, GA; 2Duke University, Durham, NC.
Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and steroids. Belatacept is a less toxic CNI alternative delivered by monthly intravenous infusion, but…2016 American Transplant Congress
Better Never Than Late: Differences in Outcomes and Risk Factors for Early and Late Rejection After Kidney Transplantation.
Medicine, University Hospitals Case Medical Center, Cleveland, OH.
Background: Late acute rejection (AR) is associated with inferior outcomes relative to early AR after kidney transplantation. We sought to examine the differences in risk…2016 American Transplant Congress
Is C3d-fixing Donor Specific HLA Antibody Detection Really Necessary?
Introduction: Chronic antibody–mediated rejection is the main cause of late kidney graft loss. The identification of donor-specific antibodies (DSA) in the serum is one of…2016 American Transplant Congress
Implications of Subclinical Borderline Acute Cellular Rejection Detected in Protocol Biopsies on Graft Outcomes.
Background: The effects of subclinical borderline acute cellular rejection (BACR-defined as I1T1 per Banff criteria) detected in protocol biopsies (Bx) on subsequent graft function and…
- « Previous Page
- 1
- …
- 415
- 416
- 417
- 418
- 419
- …
- 531
- Next Page »